Koninklijke Philips (NYSE:PHG) Sees Large Volume Increase

Koninklijke Philips (NYSE:PHG - Get Free Report) saw an uptick in trading volume on Tuesday . 1,099,348 shares changed hands during trading, a decline of 3% from the previous session's volume of 1,128,186 shares.The stock last traded at $26.88 and had previously closed at $26.71.

Analysts Set New Price Targets

A number of equities research analysts have commented on PHG shares. UBS Group upgraded Koninklijke Philips from a "sell" rating to a "neutral" rating in a research report on Tuesday. JPMorgan Chase & Co. raised shares of Koninklijke Philips from an "underweight" rating to a "neutral" rating in a research report on Tuesday. BNP Paribas downgraded shares of Koninklijke Philips from an "outperform" rating to an "underperform" rating in a research report on Wednesday, February 7th. Finally, StockNews.com raised shares of Koninklijke Philips from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $19.00.

Koninklijke Philips Stock Down 0.6 %

The stock has a market cap of $24.66 billion, a P/E ratio of -46.58, a P/E/G ratio of 1.09 and a beta of 0.88. The company has a current ratio of 1.20, a quick ratio of 0.78 and a debt-to-equity ratio of 0.58. The firm's fifty day moving average is $20.56 and its 200 day moving average is $20.99.

Koninklijke Philips (NYSE:PHG - Get Free Report) last issued its quarterly earnings results on Monday, January 29th. The technology company reported $0.44 EPS for the quarter, topping analysts' consensus estimates of $0.41 by $0.03. Koninklijke Philips had a positive return on equity of 14.17% and a negative net margin of 2.53%. The company had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.47 billion. As a group, equities research analysts forecast that Koninklijke Philips will post 1.53 EPS for the current year.

Institutional Trading of Koninklijke Philips

A number of institutional investors and hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC acquired a new stake in Koninklijke Philips during the first quarter valued at approximately $40,000. Commonwealth Equity Services LLC boosted its stake in Koninklijke Philips by 6.1% in the 1st quarter. Commonwealth Equity Services LLC now owns 55,409 shares of the technology company's stock valued at $1,108,000 after buying an additional 3,182 shares in the last quarter. Mitchell & Pahl Private Wealth LLC increased its position in shares of Koninklijke Philips by 8.2% during the 1st quarter. Mitchell & Pahl Private Wealth LLC now owns 31,568 shares of the technology company's stock worth $631,000 after purchasing an additional 2,401 shares in the last quarter. Fifth Third Bancorp lifted its holdings in Koninklijke Philips by 34.4% during the 1st quarter. Fifth Third Bancorp now owns 3,008 shares of the technology company's stock valued at $60,000 after purchasing an additional 770 shares during the last quarter. Finally, Summit Trail Advisors LLC lifted its holdings in Koninklijke Philips by 7.9% during the 1st quarter. Summit Trail Advisors LLC now owns 16,126 shares of the technology company's stock valued at $323,000 after purchasing an additional 1,186 shares during the last quarter. 13.67% of the stock is currently owned by institutional investors.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.